Glucocorticoids, Bone Strength and Angiogenesis

糖皮质激素、骨强度和血管生成

• 批准号: 8391151
• 负责人: ROBERT Stewart WEINSTEIN
• 金额: --
• 依托单位: CENTRAL ARKANSAS VETERANS HLTHCARE SYS
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-10-01 至 2013-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8391151
• 关键词: Accounting; Acid Phosphatase; Address; Adherence; Adult; Affect; Agreement; Alendronate; Angiogenic Factor; Angiogenic Peptides; Animal Model; Animals; Apoptosis; Area; Attenuated; Biological Assay; Biopsy; Biopsy Specimen; Blood Vessels; Blood flow; Bone Density; Bone Diseases; Bone remodeling; Breathing; Calcium; Cell Culture Techniques; Cells; Cessation of life; Chest wall structure; Chronic; Collagen; Data; Deterioration; Dexamethasone; Disease; Dose; Endothelial Cells; Enzymes; Estrogens; Exhibits; Fracture; Funding; Genes; Glucocorticoid Receptor; Glucocorticoids; Goals; Guidelines; HIF1A gene; Health; Healthcare; Hormones; Human; Hydroxysteroid Dehydrogenases; Hypoxia; Image; In Vitro; Intercellular Fluid; Investigation; Knowledge; Liquid substance; Lung diseases; Measurement; Messenger RNA; Metatarsal bone structure; Methodology; Minerals; Mission; Modeling; Molecular; Motivation; Mus; Osteoblasts; Osteocalcin; Osteoclasts; Osteocytes; Osteogenesis; Osteoid; Osteoporosis; Pain; Parathyroid gland; Pathogenesis; Patient Care; Patients; Perfusion; Pharmaceutical Preparations; Physical activity; Physicians; Plastics; Play; Postmenopausal Osteoporosis; Prevalence; Prevention; Process; Production; Proteins; Publishing; Raloxifene; Recruitment Activity; Research Design; Resistance; Respiratory physiology; Rib Fractures; Risk; Role; Site; Skeleton; Spinal Fractures; Splint Device; Staining method; Stains; Structure; Surface; System; Tartrates; Testing; Time; Tissues; Tracer; Transgenic Mice; Tube; Umbilical vein; Vascular Endothelial Growth Factors; Veterans; Vitamin D; Water; Weight; Woman; Work; abstracting; angiogenesis; base; bisphosphonate; bone; bone cell; bone loss; bone mass; bone strength; bone turnover; clinically significant; fetal; in vitro Assay; in vivo; innovation; insight; lead chromate; male; overexpression; prednisolone; prevent; promoter; public health relevance; research study; resilience; response; rib bone structure; skeletal; spine bone structure; tissue/cell culture; treatment strategy; vascular factor

DESCRIPTION (provided by applicant): PROJECT SUMMARY/ABSTRACT Glucocorticoid-induced osteoporosis is the most common drug-induced form of osteoporosis. Fractures may occur in 30 to 50% of patients receiving chronic glucocorticoid therapy but bone density measurements underestimate the risk of fracture in this disorder and account for, at least in part, the under- recognition and under-treatment of the disease. Vertebral and rib fractures are of particular importance to the VA patient care mission because in addition to causing pain and reducing physical activity, they can markedly decrease respiratory function in patients with pulmonary disease by causing splinting of the chest wall, thereby reducing the capacity to breathe. Glucocorticoid therapy causes a decline in bone strength that surpasses the decline in bone density, but little is known of the mechanism behind this phenomenon. Although it is widely appreciated that bone is composed of cells, mineral and collagen, it is seldom realized that water is another major component accounting for more than one fourth of the wet weight of bone. Fracture resistance of hard tissues is defective without water and water confers to bone much of its unique strength and resilience. The long-term objective of this proposal is to determine whether drug-induced deterioration of bone water and vascularity may account for the disproportionately greater decline in bone strength than in bone mass typical of glucocorticoid- induced osteoporosis and whether the bone strength and vascularity may be compromised through direct actions of glucocorticoids on bone cells. Studies aimed at the cellular and molecular mechanisms of the pathogenesis of the loss of bone strength in glucocorticoid-induced osteoporosis and investigation of the reasons for the limited response to current therapy would increase motivation to protect the skeleton as early as possible, before there are decreases in bone density. To achieve this goal, the direct effects of glucocorticoid excess on the expression of vascular proteins from bone cells will be investigated. Next, determination of the contribution of bone water and vascularity to the loss of bone strength in an animal model of glucocorticoid-induced osteoporosis and the additional impact of various treatment strategies to prevent glucocorticoid-induced osteoporosis will be examined. The clinical significance of these changes in bone vascular factors will be elucidated in humans using archival bone biopsy specimens obtained from patients with postmenopausal osteoporosis or glucocorticoid-induced osteoporosis. The studies proposed in this application are timely and by capitalizing on modern concepts and innovative methodology offer the opportunity for new insights that are sorely needed for the prevention and treatment of glucocorticoid-induced bone disease and are, therefore, immediately relevant and vital to the VA health care mission.

描述（由申请人提供）： 项目总结/摘要 糖皮质激素性骨质疏松症是最常见的药物性骨质疏松症。 骨折可能发生在30%至50%接受长期糖皮质激素治疗的患者中，但骨密度测量低估了这种疾病的骨折风险，至少部分地解释了对这种疾病的认识不足和治疗不足。 椎骨和肋骨骨折对于VA患者护理使命特别重要，因为除了引起疼痛和减少体力活动外，它们还可通过引起胸壁夹板固定而显著降低肺部疾病患者的呼吸功能，从而降低呼吸能力。 糖皮质激素治疗导致骨强度下降超过骨密度下降，但对这一现象背后的机制知之甚少。 虽然人们普遍认为骨是由细胞、矿物质和胶原蛋白组成的，但很少意识到水是另一种主要成分，占骨湿重的四分之一以上。 硬组织的抗断裂性在没有水的情况下是有缺陷的，并且水赋予骨许多其独特的强度和弹性。 本提案的长期目标是确定药物引起的骨水和血管分布恶化是否可以解释骨强度比糖皮质激素典型骨量不成比例地更大的下降。诱导的骨质疏松症和骨强度和血管是否可能通过糖皮质激素的直接作用而受到损害，骨细胞 针对糖皮质激素诱导的骨质疏松症中骨强度损失的发病机制的细胞和分子机制的研究以及对当前治疗反应有限的原因的调查将增加在骨密度降低之前尽早保护骨骼的动机。 为了实现这一目标，将研究糖皮质激素过量对骨细胞血管蛋白表达的直接影响。 接下来，将检查糖皮质激素诱导的骨质疏松症动物模型中骨水和血管分布对骨强度损失的贡献以及预防糖皮质激素诱导的骨质疏松症的各种治疗策略的额外影响。 将使用从绝经后骨质疏松症或糖皮质激素诱导的骨质疏松症患者中获得的存档骨活检标本，阐明骨血管因子这些变化的临床意义。 本申请中提出的研究是及时的，通过利用现代概念和创新方法，为糖皮质激素诱导的骨病的预防和治疗迫切需要的新见解提供了机会，因此，与VA医疗保健使命直接相关且至关重要。